At the time of writing, Galectin Therapeutics Inc [GALT] stock is trading at $6.19, up 3.17%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The GALT shares have gain 12.55% over the last week, with a monthly amount glided 21.61%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright reaffirmed its Buy rating on August 13, 2020, and elevated its price target to $12. On February 13, 2019, B. Riley FBR initiated with a Buy rating and assigned a price target of $11 on the stock. H.C. Wainwright reiterated its Buy rating and increased its price target to $10 on December 07, 2017. H.C. Wainwright reiterated its recommendation of a Buy and raised its price target to $6 on November 28, 2017. In a note dated March 30, 2017, H.C. Wainwright upgraded a Buy rating on this stock but restated the target price of $3.50.
For the past year, the stock price of Galectin Therapeutics Inc fluctuated between $0.73 and $6.55. Galectin Therapeutics Inc [NASDAQ: GALT] shares were valued at $6.19 at the most recent close of the market.
Analyzing the GALT fundamentals
Gross Profit Margin for this corporation currently stands at 0.17% with Operating Profit Margin at -693.06%, Pretax Profit Margin comes in at -1036.19%, and Net Profit Margin reading is -1036.19%. To continue investigating profitability, this company’s Return on Assets is posted at -2.9, Equity is 0.33 and Total Capital is 0.2. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.99.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.75 points at the first support level, and at 5.30 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.48, and for the 2nd resistance point, it is at 6.76.
Ratios To Look Out For
It is important to note that Galectin Therapeutics Inc [NASDAQ:GALT] has a current ratio of 0.09. As well, the Quick Ratio is 0.09, while the Cash Ratio is 0.08.
Transactions by insiders
Recent insider trading involved Jamil Khurram, Chief Medical Officer, that happened on Nov 13 ’25 when 0.12 million shares were sold. Officer, Jamil Khurram completed a deal on Nov 13 ’25 to buy 0.12 million shares. Meanwhile, 10% Owner 10X Fund, L.P. sold 40000.0 shares on Nov 11 ’25.
